未登录

K

Kenneth Kolinsky

roche holding

H指数:21

被引数:3,026

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combination of MDM2 antagonists with RAS pathway inhibitors in colorectal cancer

EUROPEAN JOURNAL OF CANCER

IF7.1

2014-11-010

PREAI

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence Implications for therapy

IF3.4

2014-10-3128

OAAI

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

CLINICAL CANCER RESEARCH

IF10.2

2014-07-1467

OAAI

Discovery of a Highly Potent, Orally Active Mitosis/Angiogenesis Inhibitor R1530 for the Treatment of Solid Tumors

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2013-01-2223

OA

Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600E colorectal cancer models

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Antitumor activity of the MDM2 antagonist, RG7112

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

CANCER RESEARCH

IF16.6

2012-02-14160

OAAI

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

CANCER RESEARCH

IF16.6

2012-01-31208

OAAI

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

MOLECULAR CANCER

IF33.9

2011-05-0341

OAAI

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097

MOLECULAR ONCOLOGY

IF4.5

2011-01-2144

OA

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

CANCER RESEARCH

IF16.6

2010-06-30415

OAAI

Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2010-01-1229

OAAI

Preclinical antitumor activity of the MEK inhibitor R05068760 in human tumor xenograft models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-12-010

PRE

Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

CANCER RESEARCH

IF16.6

2009-03-0236

OAAI

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-01-1239

PREAI

In vitro and in vivo activity of R547:: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

MOLECULAR CANCER THERAPEUTICS

IF5.5

2006-11-22118

OAAI

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T

MOLECULAR CANCER THERAPEUTICS

IF5.5

2006-08-2345

OAAI

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2006-01-27689

OAAI

RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2005-08-0124

PRE